argenx SE (ARGX.BR)
EUR 524.2
(0.15%)
EUR 524.2
(0.15%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -4.67 EUR | 63.45% |
| 2022 | -13.05 USD | -63.33% |
| 2021 | -7.99 USD | 44.24% |
| 2020 | -14.33 EUR | -202.96% |
| 2019 | -4.73 EUR | -107.46% |
| 2018 | -2.28 EUR | -66.42% |
| 2017 | -1.37 EUR | -15.13% |
| 2016 | -1.19 EUR | -12.26% |
| 2015 | -1.06 EUR | 36.14% |
| 2014 | -1.66 EUR | -207.41% |
| 2013 | -0.54 EUR | 34.15% |
| 2012 | -0.82 EUR | -182.76% |
| 2011 | -0.29 EUR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.51 EUR | 47.12% |
| 2024 Q1 | -1.04 USD | 38.82% |
| 2023 Q3 | -1.25 USD | 26.04% |
| 2023 Q1 | -0.52 USD | 25.71% |
| 2023 Q2 | -1.69 USD | -225.0% |
| 2023 FY | - EUR | 63.45% |
| 2023 Q4 | -1.68 USD | -34.4% |
| 2022 FY | - USD | -63.33% |
| 2022 Q3 | -4.26 USD | -6.23% |
| 2022 Q4 | -0.70 USD | 83.57% |
| 2022 Q1 | -4.36 USD | 6.44% |
| 2022 Q2 | -4.01 USD | 8.03% |
| 2021 Q1 | -0.81 EUR | 88.09% |
| 2021 FY | - USD | 44.24% |
| 2021 Q2 | 2.07 USD | 355.56% |
| 2021 Q3 | -4.54 USD | -319.32% |
| 2021 Q4 | -4.66 USD | -2.64% |
| 2020 Q4 | -6.80 EUR | 0.0% |
| 2020 FY | - EUR | -202.96% |
| 2020 Q2 | -4.73 EUR | 0.0% |
| 2019 Q1 | 0.20 EUR | 122.22% |
| 2019 FY | - EUR | -107.46% |
| 2019 Q4 | -2.48 EUR | -270.15% |
| 2019 Q3 | -0.67 EUR | 57.32% |
| 2019 Q2 | -1.57 EUR | -885.0% |
| 2018 Q2 | -0.04 EUR | 94.25% |
| 2018 Q3 | -0.51 EUR | -1224.68% |
| 2018 FY | - EUR | -66.42% |
| 2018 Q1 | -0.67 EUR | -48.89% |
| 2018 Q4 | -0.90 EUR | -76.47% |
| 2017 Q1 | -0.35 EUR | -9.37% |
| 2017 Q2 | -0.01 EUR | 96.57% |
| 2017 Q4 | -0.45 EUR | -45.16% |
| 2017 Q3 | -0.31 EUR | -2483.33% |
| 2017 FY | - EUR | -15.13% |
| 2016 Q3 | -0.23 EUR | -21.05% |
| 2016 Q1 | -0.21 EUR | 38.24% |
| 2016 FY | - EUR | -12.26% |
| 2016 Q2 | -0.19 EUR | 9.52% |
| 2016 Q4 | -0.32 EUR | -39.13% |
| 2015 Q2 | -0.30 EUR | -42.86% |
| 2015 FY | - EUR | 36.14% |
| 2015 Q4 | -0.34 EUR | -54.55% |
| 2015 Q3 | -0.22 EUR | 26.67% |
| 2015 Q1 | -0.21 EUR | 27.59% |
| 2014 Q2 | -0.23 EUR | -43.75% |
| 2014 Q3 | -0.11 EUR | 52.17% |
| 2014 Q4 | -0.29 EUR | -163.64% |
| 2014 FY | - EUR | -207.41% |
| 2014 Q1 | -0.16 EUR | -23.08% |
| 2013 Q2 | -0.25 EUR | -66.67% |
| 2013 Q3 | -0.01 EUR | 97.4% |
| 2013 Q4 | -0.13 EUR | -1900.0% |
| 2013 Q1 | -0.15 EUR | 0.0% |
| 2013 FY | - EUR | 34.15% |
| 2012 FY | - EUR | -182.76% |
| 2011 FY | - EUR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Nicox S.A. | -0.42 EUR | -1011.905% |
| European Medical Solutions | -0.00 EUR | -933900.0% |
| FERMENTALG | -0.32 EUR | -1359.375% |
| BioSenic S.A. | -0.21 EUR | -2123.81% |
| Celyad Oncology SA | -0.33 EUR | -1315.152% |
| Hyloris Pharmaceuticals SA | -0.55 EUR | -749.091% |
| Onward Medical N.V. | -1.20 EUR | -289.167% |
| Oxurion NV | -0.01 EUR | -40508.696% |
| PHAXIAM Therapeutics S.A. | -5.00 EUR | 6.6% |
| Financière de Tubize SA | 1.98 EUR | 335.859% |
| UCB SA | 1.81 EUR | 358.011% |